New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
16:23 EDTABBV, SHPG, NFLX, FB, TXMD, IPCI, LRCXOn The Fly: Closing Wrap
Stocks on Wall Street opened lower and stayed in negative territory for the entire session. The tech-heavy Nasdaq was weighed down by slides in a number of "momentum" stocks, while the Dow fell below 17,000 after having eclipsed that milestone for the first time to end last week. The declines came as investors prepare for earnings season, which unofficially kicked off when Alcoa (AA) reported after today's closing bell. ECONOMIC EVENTS: In the U.S., the Job Openings and Labor Turnover, or JOLTs, report showed a 171K increase in job openings to 4.635M, marking a fourth straight monthly gain. Consumer credit grew $19.6B in May, which was fairly in-line with expectations for it to be up $19.8B. COMPANY NEWS: Shares of both AbbVie (ABBV) and Shire (SHPG) fell, despite the U.S. drug company raising its takeover bid for its U.K. peer by 11% to over $51B in cash and stock. Shire responded by saying that AbbVie did not make the revised proposal to Shire before the announcement and that its board will meet to consider the revised offer. Following the announcement of the new bid, Shire shares trading in New York fell $4.55, or 1.92%, to $232.92, while AbbVie slipped $1.71, or 2.98%, to $55.69. MAJOR MOVERS: Among the notable gainers was TherapeuticsMD (TXMD), which rose $1.34, or 32.45%, to $5.47 after research firm FBR Capital initiated the stock with an Outperform rating and $34 price target. Also higher was Lam Research (LRCX), which gained $1.06, or 1.54%, to $69.67 after providing updated financial guidance at its analyst and investor meeting. Among the noteworthy losers was Intellipharmaceutics (IPCI), which fell 52c, or 13.33%, to $3.38 after reporting a net loss for its second fiscal quarter. Also lower were shares of a number of prominent technology "momentum" stocks, including Facebook (FB), which slid $2.53, or 3.88%, to $62.76, and Netflix (NFLX), which dropped $15.57, or 3.38%, to $445.05. INDEXES: The Dow lost 117.59, or 0.69%, to 16,906.62, the Nasdaq declined 60.07, or 1.35%, to 4,391.46, and the S&P 500 dropped 13.94, or 0.7%, to 1,963.71.
News For ABBV;SHPG;NFLX;FB;TXMD;IPCI;LRCX From The Last 14 Days
Check below for free stories on ABBV;SHPG;NFLX;FB;TXMD;IPCI;LRCX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
September 11, 2014
09:37 EDTNFLXActive equity options trading on open
Subscribe for More Information
07:02 EDTFBFacebook Q3 estimates have potential upside, says Citigroup
Subscribe for More Information
06:02 EDTFBFacebook implied volatility of 26 at lower end of index mean range
Subscribe for More Information
05:34 EDTABBVAbbVie reports Humira Phase 3 trial meets primary endpoint
Subscribe for More Information
September 10, 2014
16:00 EDTNFLXOptions Update; September 10, 2014
Subscribe for More Information
12:04 EDTFBFacebook testing tool that lets users schedule post deletions, The Next Web says
Facebook is testing a tool that will allow users to create self-destructing Facebook posts that disappear after a specified period of time, The Next Web reports. A spokesperson has confirmed, saying "We’re running a small pilot of a feature on Facebook for iOS that lets people schedule deletion of their posts in advance." Reference Link
10:26 EDTNFLXDiscovery CEO says likes doing deals with Netflix, Amazon
CEO David Zaslav says Comcast (CMCSA)/Time Warner Cable (TWC) deal "presents some serious issues," is talking to FCC about deal. Says will be opportunistic with international acquisitions, but "We don't feel like we need to acquire anything at this point." Says has more subscribers than ESPN with Europsport. Comments made at the Goldman Sachs Communacopia Conference.
10:24 EDTABBVEnanta announces AbbVie initiated Phase 2b trial with ABT-493
Enanta (ENTA) announced that AbbVie (ABBV) initiated a phase 2b clinical study with ABT-493, Enanta’s next-generation protease inhibitor. ABT-493 is the second clinical-stage protease inhibitor candidate developed within the Enanta-AbbVie collaboration. The phase 2b study being conducted by AbbVie will evaluate the safety and efficacy of ABT-493 co-administered with ABT-530 in HCV patients. AbbVie has informed Enanta that results from this trial are expected in 2015 and AbbVie plans to start phase 3 development of the combination next year.
10:00 EDTNFLXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:38 EDTNFLXActive equity options trading on open
Subscribe for More Information
08:37 EDTSHPGMedgenics appoints Scott Applebaum as Chief Legal Officer
Subscribe for More Information
07:06 EDTSHPGSangamo plans to submit IND application for hemophilia B in 2Q15
Sangamo BioSciences (SGMO) plans to submit an Investigational New Drug application for the treatment of hemophilia B in Q2 2015. This program, partnered with Shire (SHPG), is the first therapeutic application of Sangamo's zinc finger nuclease-mediated In Vivo Protein Replacement Platform. Sangamo is developing the IVPRP as a generally applicable strategy to provide a one-time, permanent genetic cure for monogenic diseases that are currently managed by protein replacement therapy, which involves costly repeat infusions over the lifetime of the patient.
06:26 EDTNFLXNetflix initiated with a Neutral at SunTrust
Subscribe for More Information
06:04 EDTNFLXNetflix initiated with a Buy at Canaccord
Target $550.
September 9, 2014
14:32 EDTFBApple shows Facebook, Twitter apps on Apple Watch
12:55 EDTNFLXNetflix advances after analyst ups target to $600
Subscribe for More Information
09:36 EDTNFLX, FBActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL KNDI NFLX YHOO TWTR TSLA C BAC FB MCD
08:22 EDTNFLXNetflix price target raised to $600 from $530 at RBC Capital
Subscribe for More Information
07:31 EDTNFLXNetflix enters online U.S. net neutrality strike, Reuters says
Subscribe for More Information
07:17 EDTFBThe Wireless Association to hold a conference
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use